Making the annual eye exam quick and comfortable.
Pharmacologic Mydriasis
MicroStatTM is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Almost everyone who has had an eye examination has been treated with these drugs – there are an estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the US.3 Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, by reducing the number of doses for dilation and potentially minimizing dose-related side effects (including the need to wipe away excess drug that may fall out of the eye).
3. Fernando A. Wilson, Jim P. Stimpson, and Yang Wang, “Inconsistencies Exist in National Estimates of Eye Care Services Utilization in the United States,” Journal of Ophthalmology, vol. 2015, Article ID 435606, 4 pages, 2015. https://doi.org/10.1155/2015/435606.
Learn more about our Mist-1 & 2 Study
We’re placing the power of microdosing technology in the hands of physicians and technicians. Our Mist-1 & 2 study results were presented at the ASCRS 2019 annual meeting. These results showed the efficacy and safety of the fixed combination microdose formulation and the potential for offices to improve their patient flow. Eyenovia expects to file the NDA for it’s MicroStat product in 2020.
